Crescita Therapeutics Inc.
CRRTF
$0.54
$0.00-0.37%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.16M | 15.82M | 14.54M | 13.02M | 14.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.16M | 15.82M | 14.54M | 13.02M | 14.26M |
| Cost of Revenue | 7.18M | 8.06M | 7.41M | 7.03M | 7.70M |
| Gross Profit | 7.98M | 7.75M | 7.12M | 5.99M | 6.56M |
| SG&A Expenses | 7.75M | 7.38M | 7.52M | 7.59M | 7.89M |
| Depreciation & Amortization | 526.00K | 599.20K | 549.20K | 516.30K | 555.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.87M | 16.44M | 15.90M | 15.57M | 16.61M |
| Operating Income | -709.50K | -627.70K | -1.37M | -2.55M | -2.36M |
| Income Before Tax | -29.40K | 348.40K | -957.90K | -2.21M | -2.03M |
| Income Tax Expenses | 6.50K | -10.00K | -10.00K | -10.00K | -10.00K |
| Earnings from Continuing Operations | -0.04 | 0.36 | -0.95 | -2.20 | -2.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.90K | 358.40K | -947.90K | -2.20M | -2.02M |
| EBIT | -709.50K | -627.70K | -1.37M | -2.55M | -2.36M |
| EBITDA | 261.60K | 320.50K | -471.20K | -1.69M | -1.45M |
| EPS Basic | 0.00 | 0.02 | -0.05 | -0.11 | -0.10 |
| Normalized Basic EPS | 0.02 | 0.02 | -0.03 | -0.07 | -0.07 |
| EPS Diluted | 0.00 | 0.02 | -0.05 | -0.12 | -0.11 |
| Normalized Diluted EPS | 0.02 | 0.02 | -0.03 | -0.07 | -0.07 |
| Average Basic Shares Outstanding | 75.41M | 75.92M | 76.36M | 76.87M | 77.43M |
| Average Diluted Shares Outstanding | 75.53M | 76.04M | 76.46M | 76.87M | 77.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |